Multiple hematopoietic cell lineages develop in vivo from transplanted Pax5-deficient pre-B I–cell clones

Blood ◽  
2002 ◽  
Vol 99 (2) ◽  
pp. 472-478 ◽  
Author(s):  
Christoph Schaniel ◽  
Ludovica Bruno ◽  
Fritz Melchers ◽  
Antonius G. Rolink

Abstract Pax5-deficient pre-B I–cell clones, transplanted into natural killer (NK)–cell–deficient RAG2−/−IL-2Rγ−/−hosts, populate the NK-cell compartment with functional NK cells. NK-cell generation fromPax5−/−pre-B I cells is also observed in NK-cell–proficient Balb/c RAG2−/− hosts. In the same Balb/c RAG2−/− hosts,Pax5−/− pre-B I–cell clones not only populate the pre-B I–cell compartment and fill the deficient T-cell–lineage compartment in the thymus and the periphery of all hosts, as shown before, they also generate CD8α− and CD8α+ dendritic cells (DCs), macrophages, and granulocytes in vivo in approximately half the hosts. In some recipients, practically all the mature myeloid cells are ofPax5−/− origin, indicating the effectiveness by which Pax5−/−pre-B I cells can compete with endogenous myeloid precursors. In a smaller percentage of hosts, the generation of Pax5−/−pre-B I–cell–derived erythrocytes is observed 4 to 6 months after transplantation. The results indicate that Pax5−/−pre-B I cells can develop in vivo in hosts that have undergone transplantation to erythroid, myeloid, and lymphoid cell lineages. Hence, the Pax5−/−mutation introduces an unusual instability of differentiation in pre-B I cells so that they appear to dedifferentiate as far back as the pluripotent hematopoietic stem cell.

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2340-2340
Author(s):  
Jasmine C. Wong ◽  
Kelley Weinfurtner ◽  
Yan Zhang ◽  
Pilar Alzamora ◽  
Eugene Hwang ◽  
...  

Abstract Abstract 2340 Monosomy 7 and deletion 7q [del(7q)] are among the most common cytogenetic alterations found in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). However, little is known regarding how chromosome 7 deletions contribute to the pathogenesis of myeloid malignancies. We harnessed chromosome engineering in mice to investigate the in vivo consequences of deleting a contiguous 2 Mb interval on chromosome 5A3 that is syntenic to a segment of chromosome band 7q22 that is commonly deleted in human myeloid malignancies (Blood 88:1930–5, 1996). This region contains 14 known genes, and homozygous deletion is embryonic lethal. Heterozygous 5A3+/del mice are grossly normal and have normal peripheral blood counts, but they have a 20% reduction in spleen weight and a 25% reduction in bone marrow (BM) cellularity per femur. We did not observe a significant difference in the frequency of phenotypic long-term hematopoietic stem cells (LT-HSC) (c-kit+, Sca-1+, Lin−, CD150+, CD41−, CD48−) between 5A3+/del mice and their wild-type (WT) littermates; however, there is a ∼30% reduction in the frequency of multipotent progenitors (MPP) (c-kit+, Sca-1+, Lin−, CD150−, CD41−, CD48−), suggesting a defect in the transition from LT-HSC to MPP. Since 5A3+/del mice did not spontaneously develop evidence of hematologic malignancy in >2 years of observation, and transplantation enforces enhanced HSC cycling which may reveal subtle HSC phenotypes not obvious in the steady state, we performed competitive repopulation assays to directly assess the function of 5A3+/del HSC in vivo. Unfractionated test BM from WT or 5A3+/del animals (CD45.2) were mixed with WT competitor BM (CD45.1) at a 1:1 or 1:2 ratio, followed by transplantation into lethally irradiated WT recipients (CD45.1+2). Although 5A3+/del BM supported reconstitution of all hematopoietic lineages 6 months after adoptive transfer, reductions of 46% (p=0.0003) and 45% (p=0.0010) in comparison to WT were observed in the repopulation of B and T cell lineages, respectively. Reconstitution of the myeloid lineage was reduced to a lesser extent (25% reduction; p=0.0921), and analysis of the lineage distribution of myeloid, B, and T cell lineages within 5A3+/del derived cells revealed a myeloid lineage skewing reminiscent of the pattern of repopulation exhibited by aged HSC. Interestingly, a progressive decline in the repopulating ability of 5A3+/del BM upon cell differentiation was observed: when 5A3+/del test BM were transplanted in a more stringent 1:2 test:competitor ratio, we observed a 29% reduction (p=0.1657) in contribution to the K+L−S+ (c-kit+, Lin−, Sca-1+) stem cell compartment in comparison to WT, but a 39% reduction (p=0.0498) in the more mature progenitor K+L−S− (c-kit+, Lin-, Sca-1−) population. To investigate if the marked deficit in repopulation is intrinsic to the LT-HSC population and to assess if haploinsufficiency of the 5A3 region in the microenvironment modulates the phenotype, we purified and transplanted 15 WT or 5A3+/del LT-HSC together with 250,000 unfractionated WT BM competitors into WT or 5A3+/del recipients respectively. Transplantation of 5A3+/del LT-HSC demonstrated a similar trend of global repopulating deficit and overall pattern of altered lineage distribution regardless of the genotype of the recipient, which infers a dominant cell intrinsic mechanism of action of the 5A3 deletion. Meanwhile, transplantation of WT LT-HSC into 5A3+/del recipients did not significantly modulate repopulating potential. To determine if 5A3+/del LT-HSC is defective in self-renewal, we analyzed reconstitution in the LT-HSC compartment. 5A3+/del LT-HSC repopulated the LT-HSC compartment as efficiently as WT controls regardless of the recipient genotype, and subfractionation of the 5A3+/del derived KLS population to LT-HSC and MPP subsets revealed a significantly biased distribution towards LT-HSC by 1.39-fold (p=0.0146), suggesting increased self-renewal. Together, these data demonstrate that haploinsufficiency of the 5A3 interval leads to defective HSC function including a perturbed stem cell compartment, diminished overall repopulating potential and a myeloid-biased differentiation pattern. The phenotypic resemblance to aged HSC is intriguing given the increased incidence of MDS with monosomy 7 in elderly individuals. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 119 (19) ◽  
pp. 4349-4357 ◽  
Author(s):  
Fanny Guimont-Desrochers ◽  
Geneviève Boucher ◽  
Zhongjun Dong ◽  
Martine Dupuis ◽  
André Veillette ◽  
...  

Abstract The cell lineage origin of IFN-producing killer dendritic cells (IKDCs), which exhibit prominent antitumoral activity, has been subject to debate. Although IKDCs were first described as a cell type exhibiting both plasmacytoid DC and natural killer (NK) cell properties, the current view reflects that IKDCs merely represent activated NK cells expressing B220, which were thus renamed B220+ NK cells. Herein, we further investigate the lineage relation of B220+ NK cells with regard to other NK-cell subsets. We surprisingly find that, after adoptive transfer, B220− NK cells did not acquire B220 expression, even in the presence of potent activating stimuli. These findings strongly argue against the concept that B220+ NK cells are activated NK cells. Moreover, we unequivocally show that B220+ NK cells are highly proliferative and differentiate into mature NK cells after in vivo adoptive transfer. Additional phenotypic, functional, and transcriptional characterizations further define B220+ NK cells as immediate precursors to mature NK cells. The characterization of these novel attributes to B220+ NK cells will guide the identification of their ortholog in humans, contributing to the design of potent cancer immunotherapies.


Blood ◽  
2003 ◽  
Vol 101 (11) ◽  
pp. 4342-4346 ◽  
Author(s):  
Claudiu V. Cotta ◽  
Zheng Zhang ◽  
Hyung-Gyoon Kim ◽  
Christopher A. Klug

Abstract Progenitor B cells deficient in Pax5 are developmentally multipotent, suggesting that Pax5 is necessary to maintain commitment to the B-cell lineage. Commitment may be mediated, in part, by Pax5 repression of myeloid-specific genes. To determine whether Pax5 expression in multipotential cells is sufficient to restrict development to the B-cell lineage in vivo, we enforced expression of Pax5 in hematopoietic stem cells using a retroviral vector. Peripheral blood analysis of all animals reconstituted with Pax5-expressing cells indicated that more than 90% of Pax5-expressing cells were B220+ mature B cells that were not malignant. Further analysis showed that Pax5 completely blocked T-lineage development in the thymus but did not inhibit myelopoiesis or natural killer (NK) cell development in bone marrow. These results implicate Pax5 as a critical regulator of B- versus T-cell developmental fate and suggest that Pax5 may promote commitment to the B-cell lineage by mechanisms that are independent of myeloid gene repression.


Author(s):  
Weike Pei ◽  
Fuwei Shang ◽  
Xi Wang ◽  
Ann-Kathrin Fanti ◽  
Alessandro Greco ◽  
...  

AbstractAdult bone marrow harbors a mosaic of hematopoietic stem cell (HSC) clones of embryonic origin, and recent work suggests that such clones may have coherent lineage fates. To probe under physiological conditions whether HSC clones with different fates are transcriptionally distinct, we developed PolyloxExpress – a Cre recombinase-dependent DNA substrate for in situ barcoding that allows parallel readout of barcodes and transcriptomes in single cells. We describe differentiation-inactive, multilineage and lineage-restricted HSC clones, find that they reside in distinct regions of the transcriptional landscape of hematopoiesis, and identify corresponding gene signatures. All clone types contain proliferating HSCs, indicating that differentiation-inactive HSCs can undergo symmetric self-renewal. Our work establishes an approach for studying determinants of stem cell fate in vivo and provides molecular evidence for fate coherence of HSC clones.


Blood ◽  
1995 ◽  
Vol 86 (8) ◽  
pp. 2986-2992 ◽  
Author(s):  
G de Haan ◽  
B Dontje ◽  
C Engel ◽  
M Loeffler ◽  
W Nijhof

Abstract Because of the complexity of appropriate stem cell assays, little information on the in vivo regulation of murine stem cell biology or stemmatopoiesis is available. It is unknown whether and how in vivo the primitive hematopoietic stem cell compartment is affected during a continued increased production of mature blood cells. In this study, we present data showing that prolonged (3 weeks) administration of granulocyte colony-stimulating factor (G-CSF), which is a major regulator of mature granulocyte production, has a substantial impact on both the size and the location of various stem cell subset pools in mice. We have used the novel cobblestone area forming cell (CAFC) assay to assess the effects of G-CSF on the stem cell compartment (CAFC days 7, 14, 21, and 28). In marrow, in which normally 99% of the total number of stem cells can be found, G-CSF induced a severe depletion of particularly the most primitive stem cells to 5% to 10% of normal values. The response after 7 days of G-CSF treatment was an increased amplification between CAFC day 14 and 7. However, this response occurred at the expense of the number of CAFC day 14. It is likely that the resulting gap of CAFC day 14 cell numbers was subsequently replenished from the more primitive CAFC day 21 and 28 compartments, because these cell numbers remained low during the entire treatment period. In the spleen, the number of stem cells increased, likely caused by a migration from the marrow via the blood, leading to an accumulation in the spleen. The increased number of stem cells in the spleen overcompensated for the loss in the marrow. When total body (marrow and spleen) stem cell numbers were calculated, it appeared that a continued increased production of mature granulocytes resulted in the establishment of a higher, new steady state of the stem cell compartment; most committed stem cells (CAFC day 7) were increased threefold, CAFC day 14 were increased 2.3-fold, CAFC-day 21 were increased 1.8-fold, and the most primitive stem cells evaluated, CAFC day 28, were not different from normal, although now 95% of these cells were located in the spleen. Four weeks after discontinuation of the G-CSF treatment, the stem cell reserve in the spleen had returned to a normal level, whereas stem cell numbers in marrow had recovered to values above normal. This study shows that the primitive stem cell compartment is seriously perturbed during an increased stimulation of the production of mature blood cells.(ABSTRACT TRUNCATED AT 400 WORDS)


Blood ◽  
1999 ◽  
Vol 94 (1) ◽  
pp. 333-339 ◽  
Author(s):  
Loredana Ruggeri ◽  
Marusca Capanni ◽  
Myriam Casucci ◽  
Isabella Volpi ◽  
Antonella Tosti ◽  
...  

Because of the expression of inhibitory receptors (KIR) for major histocompatibility complex (MHC) class I allotypes, a person’s natural killer (NK) cells will not recognize and will, therefore, kill cells from individuals lacking his/her KIR epitopes. This study investigated the role of NK cell alloreactivity in human HLA haplotype-mismatched hematopoietic stem cell transplantation and, specifically, the role of the three major NK specificities, ie, those for HLA-C group 1, HLA-C group 2, and HLA-Bw4 alleles. In 20 of 60 donor-recipient pairs, KIR epitope incompatibility and functional analyses of donor NK cell clones predicted donor NK cells could cause graft-versus-host (GVH)/graft-versus-leukemia (GVL) reactions. NK cell clones of donor origin were obtained from transplanted recipients and tested for lysis of recipient’s cryopreserved pretransplant lymphocytes. Despite the absence of GVH disease, we detected high frequencies of NK clones which killed recipient’s target cells. Lysis followed the rules of NK cell alloreactivity, being blocked only by the MHC class I KIR epitope which was missing in the recipient. The alloreactive NK clones also killed the allogeneic leukemia. Transplants from these KIR epitope incompatible donors had higher engraftment rates. Therefore, a GVL effector and engraftment facilitating mechanism, which is independent of T-cell–mediated GVH reactions, may be operational in HLA mismatched hematopoietic cell transplants.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 2053-2053 ◽  
Author(s):  
Sabine Herblot ◽  
Valérie Paquin ◽  
Paulo Cordeiro ◽  
Michel Duval

Abstract Despite advances in chemotherapy and hematopoietic stem cell transplantation (HSCT), the outcome of children with relapsed acute lymphoblastic leukemia (ALL) has not significantly improved over the last 2 decades. About 50% of children with relapsed leukemia still die from their disease and ALL is still the first cause of death by cancer in children. A new hope of cure for patients with chemo-resistant cancers has emerged with the development of cancer immunotherapy. However, the major risk of post-transplant immunotherapy is the exacerbation of life-threatening Graft-versus-Host Disease (GvHD) mediated by donor-derived T cells. We therefore explored the avenue of innate immune stimulation. Several reports have demonstrated that activated Natural Killer (NK) cells can control acute myeloid leukemia (AML) in transplanted patients, whereas ALL is deemed to be resistant to NK cell killing. We recently challenged this paradigm and demonstrated that the stimulation of NK cells with third-party activated plasmacytoid dendritic cells (pDC) killed most ALL cell lines and patient-derived ALL blasts. We further demonstrated the efficacy of pDC adoptive transfers to cure ALL in a humanized mouse model of HSCT. Collectively, these results uncovered for the first time the unique therapeutic potential of activated pDC as immunotherapeutic tools to stimulate NK cell anti-leukemic activity early after HSCT. The next step toward the clinical translation of pDC-based post-transplant immunotherapy is to verify that adoptive transfers of pDC do not stimulate T cells nor exacerbate GvHD in the presence of mature T cells. We designed a GMP-compliant method for in vitro expansion and differentiation of cord blood progenitors giving rise to sufficient numbers of pDC for adoptive transfers in patients. We showed that after Toll-like receptor (TLR) stimulation, these in vitro differentiated pDC displayed a phenotype of interferon producing cells (CD80neg PDL-1+) but not of antigen presenting cells (CD80+PDL-1neg). Accordingly, in vitro mixed lymphocyte reactions with purified allogeneic T cells demonstrated that TLR-activated pDC induced very low allogeneic T cell proliferation as compared with bona fide antigen presenting cells such as myeloid dendritic cells (mDC - CD11c+) or monocyte-derived dendritic cells (mo-DC) (Figure 1A). To test whether activated pDC could exacerbate GvHD in the presence of mature T cells, we used a xenoGvHD model in which human peripheral blood mononuclear cells (PBMC) were injected in immune-deficient mice (Nod/Scid/gRc-/-, NSG). We monitored GvHD 3-times a week according to a GvHD-assessment scale as previously described. Overt GvHD was characterized by cutaneous and intestinal lesions, weight loss and high numbers of human CD3+ cells in peripheral blood. Mice were sacrificed when endpoints were reached and GvHD was confirmed by immunohistochemistry and flow cytometry. Five weekly injections of TLR-activated in vitro differentiated pDC did not accelerate the GvHD onset and the severity of the lesions were not increased. We did not either observe any difference in survival between control and pDC-treated groups (Figure 1B). Collectively, our results indicate that TLR-activated pDC do not stimulate allogeneic T cells and do not increase the risk of acute GvHD in a mouse model of xenoGvHD. We therefore expect this novel pDC-based immunotherapy to be safe for transplanted patients. These data open the way for the next step: a Phase I clinical trial of in vitro differentiated pDC after transplantation for leukemia. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2008 ◽  
Vol 112 (8) ◽  
pp. 3488-3499 ◽  
Author(s):  
Luca Vago ◽  
Barbara Forno ◽  
Maria Pia Sormani ◽  
Roberto Crocchiolo ◽  
Elisabetta Zino ◽  
...  

AbstractIn this study, we have characterized reconstitution of the natural killer (NK) cell repertoire after haploidentical CD34+ selected hematopoietic stem cell transplantation (HSCT) for high-risk hematologic malignancies. Analysis focused on alloreactive single-KIR+ NK cells, which reportedly are potent antileukemic effectors. One month after HSCT, CD56bright/CD56dim NK-cell subsets showed inverted ratio and phenotypic features. CD25 and CD117 down-regulation on CD56bright, and NKG2A and CD62L up-regulation on CD56dim, suggest sequential CD56bright-to-CD56dim NK-cell maturation in vivo. Consistently, the functional potential of these maturation intermediates against leukemic blasts was impaired. Mature receptor repertoire reconstitution took at least 3 months. Importantly, at this time point, supposedly alloreactive, single-KIR+ NK cells were not yet fully functional. Frequency of these cells was highly variable, independently from predicted NK alloreactivity, and below 1% of NK cells in 3 of 6 alloreactive patients studied. In line with these observations, no clinical benefit of predicted NK alloreactivity was observed in the total cohort of 56 patients. Our findings unravel the kinetics, and limits, of NK-cell differentiation from purified haploidentical hematopoietic stem cells in vivo, and suggest that NK-cell antileukemic potential could be best exploited by infusion of mature single-KIR+ NK cells selected from an alloreactive donor.


Sign in / Sign up

Export Citation Format

Share Document